Compare OPHC & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPHC | XBIT |
|---|---|---|
| Founded | 2000 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5M | 69.8M |
| IPO Year | 2012 | 2015 |
| Metric | OPHC | XBIT |
|---|---|---|
| Price | $7.58 | $2.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | ★ 73.2K | 39.8K |
| Earning Date | 04-24-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17,095.98 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.91 | $2.09 |
| 52 Week High | $7.35 | $3.61 |
| Indicator | OPHC | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 82.90 | 38.13 |
| Support Level | $5.33 | $2.18 |
| Resistance Level | N/A | $2.42 |
| Average True Range (ATR) | 0.24 | 0.05 |
| MACD | 0.13 | -0.00 |
| Stochastic Oscillator | 95.54 | 35.71 |
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.